182 related articles for article (PubMed ID: 36687558)
1. Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey.
Tagliamento M; Remon J; Giaj Levra M; De Maria A; Bironzo P; Besse B; Novello S; Mezquita L
JTO Clin Res Rep; 2023 Jan; 4(1):100446. PubMed ID: 36687558
[TBL] [Abstract][Full Text] [Related]
2. Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Mustafayev K; Mallet V; Torres HA
J Immunother Precis Oncol; 2024 May; 7(2):111-121. PubMed ID: 38721408
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review.
Pu D; Yin L; Zhou Y; Li W; Huang L; Cai L; Zhou Q
Medicine (Baltimore); 2020 Jan; 99(5):e19013. PubMed ID: 32000444
[TBL] [Abstract][Full Text] [Related]
4. Management of autoimmune and viral hepatitis in immunotherapy: a narrative review.
Kuo L; Kuwelker S; Tsai E
Ann Palliat Med; 2023 Nov; 12(6):1275-1294. PubMed ID: 37731304
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection.
Shah NJ; Al-Shbool G; Blackburn M; Cook M; Belouali A; Liu SV; Madhavan S; He AR; Atkins MB; Gibney GT; Kim C
J Immunother Cancer; 2019 Dec; 7(1):353. PubMed ID: 31847881
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection.
Pertejo-Fernandez A; Ricciuti B; Hammond SP; Marty FM; Recondo G; Rangachari D; Costa DB; Awad MM
Lung Cancer; 2020 Jul; 145():181-185. PubMed ID: 32423643
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review.
Zhao J; Zhang Y; Qin S; Zou B; Wang Y
J Cancer; 2022; 13(14):3539-3553. PubMed ID: 36484006
[No Abstract] [Full Text] [Related]
8. Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection.
Alkrekshi A; Tamaskar I
Oncologist; 2021 May; 26(5):e827-e830. PubMed ID: 33655663
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection.
Nakabori T; Abe Y; Higashi S; Hirao T; Kawamoto Y; Maeda S; Daiku K; Urabe M; Kai Y; Takada R; Yamai T; Ikezawa K; Uehara H; Ohkawa K
JGH Open; 2022 May; 6(5):309-316. PubMed ID: 35601125
[TBL] [Abstract][Full Text] [Related]
10. Managing viral hepatitis in cancer patients under immune checkpoint inhibitors: should we take the risk?
De Keukeleire SJ; Vermassen T; Nezhad ZM; Kerre T; Kruse V; Vlierberghe HV; Vermaelen K; Rottey S
Immunotherapy; 2021 Apr; 13(5):409-418. PubMed ID: 33487052
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Xia Z; Zhang J; Chen W; Zhou H; Du D; Zhu K; Chen H; Meng J; Yang J
Infect Dis Poverty; 2023 Sep; 12(1):87. PubMed ID: 37736699
[TBL] [Abstract][Full Text] [Related]
12. The Low Incidence of Viral Hepatitis Reactivation Among Subjects on Immunotherapy Reduces the Impact of Suboptimal Screening Rate.
Aceituno L; Bañares J; Ruiz-Ortega L; Callejo-Pérez A; Muñoz-Couselo E; Ortiz-Velez C; Díaz-Mejía N; Barreira-Díaz A; Carreras MJ; Farriols A; Buti M; Riveiro-Barciela M
Front Med (Lausanne); 2022; 9():916213. PubMed ID: 35911389
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies.
Mustafayev K; Torres H
Clin Microbiol Infect; 2022 Oct; 28(10):1321-1327. PubMed ID: 35283317
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of immune checkpoint inhibitors differs in various status of carcinoma: a study based on 29 cohorts with 3255 participants.
Wu C; Ke Y; Wan L; Xie X
Cancer Immunol Immunother; 2024 Mar; 73(5):79. PubMed ID: 38554165
[TBL] [Abstract][Full Text] [Related]
15. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.
Lee PC; Chao Y; Chen MH; Lan KH; Lee IC; Hou MC; Huang YH
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32863270
[TBL] [Abstract][Full Text] [Related]
16. Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment.
Yoo S; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Yoo C; Ryoo BY; Choi J
Clin Gastroenterol Hepatol; 2022 Apr; 20(4):898-907. PubMed ID: 34182151
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience.
Nardo M; Yilmaz B; Nelson BE; Torres HA; Wang LS; Granwehr BP; Song J; Dalla Pria HRF; Trinh VA; Glitza Oliva IC; Patel SP; Tannir NM; Kaseb AO; Altan M; Lee SS; Miller E; Zhang H; Stephen BA; Naing A
Oncologist; 2023 Aug; 28(8):714-721. PubMed ID: 36952233
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices.
Ramsey SD; Unger JM; Baker LH; Little RF; Loomba R; Hwang JP; Chugh R; Konerman MA; Arnold K; Menter AR; Thomas E; Michels RM; Jorgensen CW; Burton GV; Bhadkamkar NA; Hershman DL
JAMA Oncol; 2019 Apr; 5(4):497-505. PubMed ID: 30653226
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection.
Megna M; Patruno C; Bongiorno MR; Gambardella A; Guarneri C; Romita P; Raimondo A; Loconsole F; Fabbrocini G
Clin Drug Investig; 2022 Jun; 42(6):525-531. PubMed ID: 35633470
[TBL] [Abstract][Full Text] [Related]
20. Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy.
Ziogas DC; Kostantinou F; Cholongitas E; Anastasopoulou A; Diamantopoulos P; Haanen J; Gogas H
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
